OnKure Therapeutics, Inc. (NASDAQ:OKUR) — Market Cap & Net Worth
Market Cap & Net Worth: OnKure Therapeutics, Inc. (OKUR)
OnKure Therapeutics, Inc. (NASDAQ:OKUR) has a market capitalization of $119.87 Million ($119.87 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #18594 globally and #4325 in its home market, demonstrating a -12.43% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying OnKure Therapeutics, Inc.'s stock price $2.96 by its total outstanding shares 40496309 (40.50 Million). Also see OnKure Therapeutics, Inc. total assets for a full breakdown of the balance sheet.
OnKure Therapeutics, Inc. Market Cap History: 2021 to 2026
OnKure Therapeutics, Inc.'s market capitalization history from 2021 to 2026. Data shows change from $3.46 Billion to $119.87 Million (-51.36% CAGR). Also see how efficiently does OnKure Therapeutics, Inc. generate cash for how efficiently the company converts equity into cash flow.
Index Memberships
OnKure Therapeutics, Inc. is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.67 Trillion | 0.00% | #523 of 976 |
Weight: OnKure Therapeutics, Inc.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
OnKure Therapeutics, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how OnKure Therapeutics, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check current stock price of OnKure Therapeutics, Inc. for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of OKUR by Market Capitalization
Companies near OnKure Therapeutics, Inc. in the global market cap rankings as of September 18, 2026. Review OnKure Therapeutics, Inc. (OKUR) tangible net worth to assess the quality of the company's equity after excluding intangible assets.
Key companies related to OnKure Therapeutics, Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.87 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #337 globally with a market cap of $79.84 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.95 Billion USD ( AU$86.14 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #504 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.87 Billion | $516.34 |
| #337 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.84 Billion | $789.45 |
| #455 | CSL Ltd | AU:CSL | $60.95 Billion | AU$177.56 |
| #504 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $158.07 |
OnKure Therapeutics, Inc. Historical Marketcap From 2021 to 2026
Between 2021 and today, OnKure Therapeutics, Inc.'s market cap moved from $3.46 Billion to $ 119.87 Million, with a yearly change of -51.36%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $119.87 Million | +2.07% |
| 2025 | $117.44 Million | -66.28% |
| 2024 | $348.27 Million | -46.25% |
| 2023 | $647.94 Million | -31.33% |
| 2022 | $943.56 Million | -72.75% |
| 2021 | $3.46 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of OnKure Therapeutics, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $119.87 Million USD |
| MoneyControl | $119.87 Million USD |
| MarketWatch | $119.87 Million USD |
| marketcap.company | $119.87 Million USD |
| Reuters | $119.87 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About OnKure Therapeutics, Inc.
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatmen… Read more